227 related articles for article (PubMed ID: 31305262)
1. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.
Spudich S; Robertson KR; Bosch RJ; Gandhi RT; Cyktor JC; Mar H; Macatangay BJ; Lalama CM; Rinaldo C; Collier AC; Godfrey C; Eron JJ; McMahon D; Jacobs JL; Koontz D; Hogg E; Vecchio A; Mellors JW
J Clin Invest; 2019 Jul; 129(8):3339-3346. PubMed ID: 31305262
[TBL] [Abstract][Full Text] [Related]
2. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations.
Oliveira MF; Chaillon A; Nakazawa M; Vargas M; Letendre SL; Strain MC; Ellis RJ; Morris S; Little SJ; Smith DM; Gianella S
PLoS Pathog; 2017 Jan; 13(1):e1006112. PubMed ID: 28046096
[TBL] [Abstract][Full Text] [Related]
3. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.
Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR
J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220
[TBL] [Abstract][Full Text] [Related]
4. Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR.
de Oliveira MF; Gianella S; Letendre S; Scheffler K; Kosakovsky Pond SL; Smith DM; Strain M; Ellis RJ
PLoS One; 2015; 10(10):e0139510. PubMed ID: 26431315
[TBL] [Abstract][Full Text] [Related]
5. (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study.
Hoenigl M; de Oliveira MF; Pérez-Santiago J; Zhang Y; Morris S; McCutchan AJ; Finkelman M; Marcotte TD; Ellis RJ; Gianella S
Medicine (Baltimore); 2016 Mar; 95(11):e3162. PubMed ID: 26986173
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
[TBL] [Abstract][Full Text] [Related]
7. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults.
Patton SM; Wang Q; Hulgan T; Connor JR; Jia P; Zhao Z; Letendre SL; Ellis RJ; Bush WS; Samuels DC; Franklin DR; Kaur H; Iudicello J; Grant I; Kallianpur AR
Fluids Barriers CNS; 2017 Apr; 14(1):11. PubMed ID: 28427421
[TBL] [Abstract][Full Text] [Related]
9. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.
Letendre S; Bharti A; Perez-Valero I; Hanson B; Franklin D; Woods SP; Gianella S; de Oliveira MF; Heaton RK; Grant I; Landay AL; Lurain N;
Clin Infect Dis; 2018 Aug; 67(5):770-777. PubMed ID: 29506084
[TBL] [Abstract][Full Text] [Related]
10. Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study.
Anderson AM; Tang B; Vaida F; Mcclernon D; Deutsch R; Cherner M; Cookson D; Crescini M; Grant I; Ellis RJ; Letendre SL
J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1196-1204. PubMed ID: 33901102
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
[TBL] [Abstract][Full Text] [Related]
12. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
13. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
[TBL] [Abstract][Full Text] [Related]
14. Clinical factors related to brain structure in HIV: the CHARTER study.
Jernigan TL; Archibald SL; Fennema-Notestine C; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Wolfson T; Letendre SL; Ellis RJ; Heaton RK; Gamst AC; Franklin DR; Clifford DB; Collier AC; Gelman BB; Marra C; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I;
J Neurovirol; 2011 Jun; 17(3):248-57. PubMed ID: 21544705
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND).
Schrier RD; Hong S; Crescini M; Ellis R; Pérez-Santiago J; Spina C; Letendre S;
PLoS One; 2015; 10(2):e0116526. PubMed ID: 25719800
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
Christo PP; Greco DB; Aleixo AW; Livramento JA
BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
